We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.19 | 4.92% | 4.05 | 3.30 | 4.80 | - | 72,225 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 8.58 | 11.39M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/4/2021 11:40 | Jeffian Looks like you have some Qs for the Q&A Re costs, bear in mind that TMT Pro, the and work on new tryptophan and AD assays did add to costs, but were scaled back, although I forget when Does your lack of explaining what you felt was incorrect in my earlier post mean that you now see you were mistaken Jeffers? Not like you to miss the opportunity to prove someone wrong | stocktastic | |
01/4/2021 11:36 | BOL! What a silly billy. | tom barnaby | |
01/4/2021 11:31 | Some made-up nonsense about the test already being sold to customers. | monte1 | |
01/4/2021 11:28 | I note that Randox_Richard has edited the post. What did the original 'say'? | tom barnaby | |
01/4/2021 11:23 | Good point and very well made imco. C’mon the PRM | monte1 | |
01/4/2021 11:21 | #88766, Well indeed they did at the time, pools2, and I think I even mentioned £10m when their overheads were running at a "stable" £5m/year. The point is that all the improvement at the moment is down to cost-cutting, not a huge improvement in revenues or profitability. | jeffian | |
01/4/2021 11:17 | Once more pools2 - this time in English please. tia Edit - translated version now noted. | monte1 | |
01/4/2021 11:16 | Coming from our self professed expert who was telling us a short while ago that PRM needed £6.5 million revenue just to break even. | pools2 | |
01/4/2021 11:11 | Well it's hard to fathom what is going on but at the heart of it we have a company which is less profitable at the operating level but has generated cash and a better bottom line by slashing administrative costs in an inexplicable way. The huge improvement in the second half comes entirely from the massive drop in Administrative Expenses (a mere £654k apparently against previous half-years when it has been running at c.£1.2-£1.3m). I'm also interested to note that they show total Administrative expenses for the year down to £2.036m and yet staff costs alone are £2.15m. How does that work? There is a blurring of Operating and Administrative costs into 'total costs' but the plain fact is that the Gross Profit margin has remained pretty constant for years around 55% producing a GP this year of £550k to run the business. Hmmmm. | jeffian | |
01/4/2021 11:06 | This co is now profitable with a decent outlook over next 3-5yrs. A good place to be IMO. W41 | wrighty41 | |
01/4/2021 10:41 | Ah well, we didn't get to where we are today by over-delivering ... | small crow | |
01/4/2021 10:40 | Lol If we hadn't hired the above CEO. we would have had £500,000 profit. | madmick | |
01/4/2021 10:17 | Good morning Randhoax_Girl | monte1 | |
01/4/2021 10:14 | Investor Presentation Proteome Sciences PLC is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Company's results for the year ended 31 December 2020 via the Investor Meet Company platform on Thursday, 8 April 2021 at 10.00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and select to meet Proteome Sciences PLC via: Investors who already follow Proteome Sciences PLC on the Investor Meet Company platform will automatically be invited. | elpirata | |
01/4/2021 09:37 | Slightly underwhelmed by the results | the bull | |
01/4/2021 09:36 | Why doesn't PRM tell us about their recent Ck1d therapeutic patent grant on 27th October last year in their final results for 2020 today ??? Answers on a postcard please | wasjobber | |
01/4/2021 09:31 | goatherd 29 Mar '21 - 18:35 - 58753 of 58789 0 4 0 I have a suspicion (entirely without evidence) that the demand could be coming from the Randox side as I am expecting their CE anytime BOL! | elpirata | |
01/4/2021 09:30 | quite right monte1, I note the re-rating is in play | elpirata | |
01/4/2021 09:05 | They are not having mine cheap. | monte1 | |
01/4/2021 09:02 | Now they are going to bore you out of your shares | mashman | |
01/4/2021 09:00 | As you were!!!!. | peverill | |
01/4/2021 08:39 | I note that the increase in cash was primarily due to a significant Prepayment and 'managing' creditors. | tom barnaby | |
01/4/2021 08:37 | A little bit more than expected ten times more! | csmwssk12hu | |
01/4/2021 08:35 | How veerrry dare you. | monte1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions